SuperTROPO (Better Diagnostics of Myocardial Infarction With a Test for Special Forms of Troponin)

Myocardial Infarction Clinical Trial

— SuperTROPO  

Official title:

SuperTROPO (Better Diagnostics of Myocardial Infarction With a Test for Special Forms of Troponin)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05858112
• Other study ID #: VARHA/487/13.02.02/2023
• Status: Recruiting
• Start date: May 1, 2023
• Est. completion date: December 2025

Study information

• Verified date: November 2023
• Source: Turku University Hospital
• Contact: Konsta Teppo
• Phone: 00358415027333
• Email: jkitep[@]utu.fi
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The aim of this study is to investigate whether measurement of the long forms of cTnT with the novel SuperTROPO assay would improve the diagnosis of myocardial infarction in patients in the emergency department. The main goals are:

1. To assess whether measuring long forms of cTnT with the novel SuperTROPO assay and determining the ratio of long cTnT and standard high-sensitivity cTnT could separate patients with type 1 NSTEMI patients from patients with other causes of minor (> 14ng/L) cTnT elevation in a single admission blood sample in unselected emergency department patients with clinical indication for troponin measurement.

2. To compare the level of long cTnT and the ratio of long cTnT and standard cTnT in patients with type 1 MI and various clinical patient groups admitted to emergency department with elevated standard cTnT, e.g. patients with atrial fibrillation, heart failure or renal impairment.

3. To evaluate optimal cut-off values for long cTnT and its ratio to standard cTnT in the exclusion and diagnosis of MI in a clinical setting with elevated (>14ng/L) cTnT.

4. To evaluate how time from symptom onset and peak symptom to blood sampling, as well as comorbidities and patients' age impact the discriminative capacity of long cTnT and cTnT ratio between patients with and without type 1 MI.

5. To investigate whether information on long cTnT and its ratio to standard cTnT can be used to cut down unnecessary coronary angiographies and hospital admissions

The long forms of cTnT are measured from the residual blood samples routinely collected from patients with suspected myocardial infarction.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 3000
• Est. completion date: December 2025
• Est. primary completion date: November 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years to 110 Years

Eligibility

Inclusion Criteria:

• Patient has arrived at the emergency department and high-sensitivity cTnT test (P-TnT) has been ordered as part of the routine "cardiac package" of laboratory tests upon arrival

• Result of >14 ng/L of the P-TnT test included in the "cardiac package"

• Age > 18

• The patient or his/her legal representative has given written informed consent for participation in the study

Exclusion Criteria:

• unable to give informed consent

• legally incompetent individuals

• pregnancy

• previously participated in this study

Related Conditions & MeSH terms

• Coronary Artery Disease
• Infarction
• Ischemia
• Myocardial Infarction
• Myocardial Ischemia

Intervention

Diagnostic Test:
• SuperTROPO novel assay to measure the long forms of cTnT
SuperTROPO novel assay to measure the long forms of cTnT

Locations

Country	Name	City	State
Finland	Turku University Hospital	Turku

Sponsors (2)

Lead Sponsor	Collaborator
Turku University Hospital	University of Turku

Country where clinical trial is conducted

Finland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Myocardial infarction type 1	In brief, type 1 MI will be diagnosed when there is evidence of myocardial necrosis along with a clinical setting consistent with acute myocardial ischemia, as well as a coronary plaque rupture or erosion and superimposed thrombosis. The presence of the final diagnosis of type 1 MI by the treating clinician will be reviewed from patient records of the index hospitalization. Furthermore, patients with type 2 MI, will be identified and analyzed separately. The proportion of patients with type MI will be calculated and troponin values will be compared with patients with and without MI. .	During the index hospitalization, that is, the hospitalization after the drawn blood samples at the emergency department. Up to 12 weeks.